Bioavailability of Different Formulations of Metformin Hydrochloride in Healthy Volunteers: a Comparative Study

Authors

  • Edilson Martins Rodrigues Neto Centre for Drug Research and Development, Federal University of Ceará (UFC), Fortaleza, CE, Brazil
  • Lídia Audrey Rocha Valadas Marques Centre for Drug Research and Development, Federal University of Ceará (UFC), Fortaleza, CE, Brazil
  • Gilmara Holanda da Cunha Department of Nursing, Federal University of Ceará (UFC), Fortaleza, CE, Brazil
  • Andrea Vieira Pontes Centre for Drug Research and Development, Federal University of Ceará (UFC), Fortaleza, CE, Brazil; Federal University of Ceará
  • Patrícia Leal Dantas Lobo Dentistry Course, Campus Sobral, Federal University of Ceará (UFC), Sobral, CE, Brazil
  • Gilberto de Nucci Department of Pharmacology, University of São Paulo (UFC), São Paulo, SP, Brazil
  • Manoel Odorico de Moraes Centre for Drug Research and Development, Federal University of Ceará (UFC), Fortaleza, CE, Brazil
  • Maria Elisabete Amaral de Moraes Centre for Drug Research and Development, Federal University of Ceará (UFC), Fortaleza, CE, Brazil

DOI:

https://doi.org/10.3823/2171

Keywords:

Therapeutic equivalency, biological availability, clinical trial, metformin

Abstract

Objective: To assess the bioavailability of a formulation of metformin hydrochloride 850 mg coated tablets as test, compared to a reference product with the same dosage form, in healthy volunteers of both genders. Method: This clinical trial was designed as randomised, comparative, single-dose, open-label, two-period, two-sequence, crossover study under fasting conditions. 28 healthy volunteers (fourteen men and fourteen women) took part in the study. The 850 mg coated tablets formulations were administered in a single dose orally. Blood samples were obtained prior to dosing and at 30 min, 1, 1:20; 1:40, 2, 2:20, 2:40; 3, 3:20, 3:40 4, 4:30, 5, 6, 8, 12, 16, 24 and 36 hours after drug administration with an one week washout period. Plasmatic concentrations of metformin were measured by specific and validated analytical methods based on high-performance liquid chromatography coupled to mass spectrometry (HPLC/MS). The pharmacokinetics parameter AUC0-36h, AUC0-∞ and Cmax were tested for bioequivalence after log transformation of data and ratios of Tmax were evaluated non parametrically. Findings: Data from this study showed that the test and the reference formulation presented similar results, within the acceptance range (80-125%) for AUC0-∞ (area under curve) and Cmax (maximum serum concentration of the drug) parameters, satisfying the bioequivalence criteria of the Brazilian Health Surveillance Agency and FDA. Conclusion: These results indicate that the two formulations of metformin hydrochloride 850 mg coated tablets are bioequivalent, thus, it will be possible to ensure interchangeability between them, which can generate market competition and better access to this treatment.

References

Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell. 2012;148:1160-71. Available from: http://dx.doi.org/10.1016/j.cell.2012.02.010

Rodrigues Neto EM, Marques LARV, Ferreira MAD, Lobo PLD, Girão Júnior FJ, Camarão GC, et al. Metformina: uma revisão da literatura. Saúde e Pesquisa. 2015;8:355-62. Available from: http://dx.doi.org/10.17765/1983-1870.2015v8n2p355-362

Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168:2088-94. Available from: https://dx.doi.org/10.1001%2Farchinte.168.19.2088

Van Der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS ONE. 2011;6:e23611. Available from: http://dx.doi.org/10.1371/journal.pone.0023611

Robert F, Fendri S, Hary L, Lacroix C, Andréjak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab. 2003;29:279-83. Available from: http://www.em-consulte.com/en/article/80210

Hu LD, Liu Y, Tang X, Zhang Q. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets. Eur J Pharm Biopharm. 2006;64:185-92. Available from: http://dx.doi.org/10.1016/j.ejpb.2006.04.004

Al Hawari S, AlGaai E, Yusuf A, Abdelgaleel A, Hammami MM. Bioequivalence study of two metformin formulations. Arzneimittelforschung. 2007;57:192-5. Available from: http://dx.doi.org/10.1055/s-0031-1296605

Porta V, Schramm SG, Kano KE, Koono EE, Armando YP, Fukuda K, Serra CHR. HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. J Pharm Biomed Anal. 2008;46:143-7. Available from: http://dx.doi.org/10.1016/j.jpba.2007.10.007

Souza FC, Marques EB, Scaramello CBV. Variações interindividuais na farmacocinética clínica de cardiotônicos. Rev Bras Cardiol. 2013;26:213-20. Available from: http://www.rbconline.org.br/artigo/variacoes-interindividuais-na-farmacocinetica-clinica-de-cardiotonicos/

Costa VM, Bastos ML, Carvalho F. Género masculino vs feminino: factor relevante para as respostas farmacológicas e efeitos adversos de fármacos? Acta Farmacêutica Portuguesa. 2011;1:55-64. Available from: http://www.actafarmaceuticaportuguesa.com/index.php/afp/article/view/32

Motta ELA, Domingues TS, Soares Júnior JM. O uso de sensibilizadores de insulina no tratamento de infertilidade em pacientes com síndrome dos ovários policísticos (SOP). Rev Bras Ginecol Obstet, 2012;34:99-101. Available from: http://dx.doi.org/10.1590/S0100-72032012000300001

Campo-Arias A, Herazo YE. Cefalea como síntoma de abstinencia a la cafeína: un estudio poblacional. Rev. fac. med. 2008;16:176-83. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-52562008000200005&lng=en

Cruzado L, Sánchez-fernández M, Cortez-Vergara C, Rojas-Rojas G. Manía inducida por bebidas energéticas con alto contenido de cafeína. Actas Esp Psiquiatr. 2014;42:259-66. Available from: http://actaspsiquiatria.es/repositorio/16/91/ESP/16-91-ESP-259-262-556333.pdf

Downloads

Published

2016-11-10

Issue

Section

Toxicology & Therapeutics

Most read articles by the same author(s)